This discrepancy may be explained by the fact that bicalutamide did show a small amount of efficacy in reducing tumor size and PSA levels, indicative of PCa progression slowing and therefore androgen signaling decreasing; however, further studies should be conducted to provide a more clear explanation. This evidence concerns the gene KLK3 and neoplasm.